Clinical Trial Update: Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating afatinib in combination with paclitaxel as neoadjuvant therapy for triple-negative breast cancer, with biomarker rese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Gilotrif (Afatinib)
• Taxol (paclitaxel)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN